NCT04225936

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

An Open-label, Two-Part, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	BMS-986263	Single Dose

Timeline

• Start date: 2020-01-16
• Primary completion: 2021-06-01
• Completion: 2021-06-01
• First posted: 2020-01-13
• Last updated: 2021-11-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study